Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Bernstein Upgrades Eni to Outperform

Bernstein Upgrades Eni to Outperform

Bernstein analyst Oswald Clint upgrades Eni (NYSE:E) from Market Perform to Outperform.

byBenzinga Newsdesk

January 3, 2023

1 minute read

Bernstein analyst Oswald Clint upgrades Eni (NYSE:E) from Market Perform to Outperform.

Analyst Ratings

Analyst Ratings for Procter & Gamble

By Benzinga Insights

September 8, 10:00 AM

Procter & Gamble (NYSE:PG) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having Hypercortisolism

By Benzinga Newsdesk

February 15, 5:25 PM

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

CORT

News

Hestia Capital Partners Reports In 13D Filing A 6.9% Stake In Pitney Bowes

By Benzinga Newsdesk

November 21, 10:20 AM

-SEC Filing

PBI

BofA: US Dollar’s Dominance, Privilege Are Here To Stay – BRICS, Yuan & Crypto Are Not Alternatives

By Piero Cingari

May 4, 1:21 PM

The global dominance of the US dollar is not in any way under threat, as no other currency alternatives are available.

UUP

Bernstein Upgrades Eni to Outperform

Related Posts

Analyst Ratings for Procter & Gamble

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having Hypercortisolism

Hestia Capital Partners Reports In 13D Filing A 6.9% Stake In Pitney Bowes

BofA: US Dollar’s Dominance, Privilege Are Here To Stay – BRICS, Yuan & Crypto Are Not Alternatives